An antibody's increased tendency to bind itself at high concentrations limits its stability. As such, scientists must carefully characterize self-interaction when selecting molecules for pharmaceutical applications. However, researchers often have only scarce sample amounts during early-stage development, which prevents them from using many self-interaction analysis methods. Techniques to assess antibody self-interactions with only micrograms of protein are urgently needed.
In this webinar, brought to you by Sartorius, Martin Domnowski, a former researcher at the Ludwig Maximilian University of Munich, will discuss how Bio-Layer Interferometry (BLI) quickly and reliably identifies antibodies with a strong tendency for self-interaction. Moreover, he will present mitigation strategies for reducing antibody self-interaction, such as specific formulation excipients and rational mutagenesis.
Topics to be covered
Antibody self-interaction in pharmaceutical drug development
Using Octet® BLI technology for monoclonal antibody formulation development
Identifying antibody variants with lower self-interaction tendencies
Wednesday, March 16, 2022
10:00 AM Eastern Time (3:00 PM CET)
This webinar will also be available on-demand.
Meet the speakers
Martin Domnowski, PhD Pharmaceutical Technology and Biopharmaceutics Ludwig Maximilian University
David Apiyo, PhD Manager of Applications Scientists
BioAnalytics Applications
Sartorius
Sponsored by
Register
TS_Webinar_Bio-Rad_LabTools_Droplet Digital PCR: When qPCR Doesn’t Make the Cut November 4, 2021_IO#403220
You must have Javascript and Cookies enabled to access this webcast.
Information you provide will be shared with the sponsors for this content. The Scientist or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
